Wednesday, 18 July 2012

Στρωματικοί όγκοι του πεπτικού (μ. ΒΙΒΛΙΟΓΡΑΦΙΑ)

1. Golden T., Stout A.P.: Smooth Muscle Tumors of the Gastrointestinal Tract and Retroperitoneal Tissues. Surg Gynecol Obstet 1941;73:784-810

2. Stout A.P.: Bizzare Smooth Muscle Tumors of the Stomach. Cancer 1962; 15: 400-409

3. Appelman H.D.: Smooth Muscle Tumors of the Gastrointestinal Tract. What we know now that Stout didn’t know. Am J Surg Pathol 1986; 10(suppl.1): 83-93

4. Mazur M.T., Clark H.B.: Gastric Stromal Tumors. Reappraisal of Histogenesis. Am J Surg Pathol 1983; 7: 507-519

5. Kindblom L.G., Remotti H.E., Aldenborg F., Meis-Kindblom J.M.: Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of Cajals. Am J Pathol 1998; 152:1259-1269

6. Nishida T., Hirota S.: Biological and Clinical Review of Stromal Tumors in the Gastrointestinal Tract. Hist Histopathol 2000;15: 1293-1301

7. Miettinen M., Lasota J.: Gastrointestinal Stromal Tumors – Definition, Clinical, Histological, Immunohistochemical and Molecular Genetic Features and Differential Diagnosis. Virchows Arch 2001; 438: 1-12

8. El-Rifay W., Sarlomo-Ricala M., Miettinen M., et al.: DNA Copy Number Losses in Chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res 1996; 56: 3230-3233

9. Bergman F., Gunawan B., Hermanns B., et al.: Cytogenetic and Morphologic Characteristics of Gastrointestinal Stromal Tumors. Recurrent Rearrangement of Chromosome 1 and Losses of Chromosomes 14 and 22 as Common Anomalies. Verh Dtsch Ges Pathol 1998; 82: 275-278

10. O’Leary T., Ernst S., Przygodzki R., et al.: Loss of Heterozygosity at 1p36 Predicts Poor Prognosis in Gastrointestinal Stromal/Smooth Muscle Tumors. Lab Invest 1999; 79: 1461-1467

11. Fukasawa T., Chong J.M., Sakurai S., et al.: Allelic Loss of 14q and 22q, NF2 Mutation, and Genetic Instability Occur Independently of c-Kit Mutation of Gastrointestinal Stromal Tumor. Jpn J Cancer Res 2000; 91: 1241-1249

12. Debiek-Rychter M., Lasota J., Sarlomo-Rikala M., et al.: Chromosomal Aberrations in Malignant Gastrointestinal Stromal Tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 2001; 128: 24-30

13. Heinrich M.C., Rubin B.P., Longley B.J., Flecher J.A.: Biology and Genetic Aspects of Gastrointestinal Stromal Tumors: Kit activation and cytogenetic alterations. Hum Pathol  2002; 33: 484-495

14. Heinrich M.C., Corless C.L., Duensing A., et al.: PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science 2003; 299: 708-710

15. Antonescu C.R., Viale A., Sarran L., et al.: Gene Expression in Gastrointestinal Stromal Tumors is Distinguished by KIT Genotype and Anatomic Site. Clin Cancer Res 2004; 10: 3282-3290

16. El-Rifay W., Sarlomo-Ricala M., Anderson L.C., et al.: High-resolution Deletion Mapping of Chromosome 14 in Stromal Tumors of the Gastrointestinal Tract Suggests Two Distinct Tumor Suppressor Loci. Genes Chromosomes Cancer 2000; 27: 387-391

17. El-Rifay W., Sarlomo-Ricala M., Anderson L.C., et al.: DNA Sequence Copy Number Changes in Gastrointestinal Stromal Tumors: tumor progression and prognostic signicance. Cancer Res 2000; 60: 3899-3903

18. Hirota S., Isozaki K., Moriyama Y. et al: Gain of Function Mutations of c-KIT in Human G.I. Stromal Tumors. Science 1998; 279: 577-580

19. Nakahara M., Isozaki K., Hirota S. et al: A Novel Gain-of Function Mutation of c-KIT Gene in Gastrointestinal Stromal Tumors. Gastroenterology 1998; 115: 1090-1095

20. Rubin B.P., Singer S., Tsao L. et al: Kit Activation is a Ubiquitus Feature of Gastrointestinal Stromal Tumors. Cancer Res 2001; 61: 8118-8121

21. Corless C.L., McGreevy L., Haley A. et al.: KIT mutations are common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in Size. Am J Pathol 2002; 160: 1567-1572

22.  Lux M.L., Rubin B.P., Biase T.L. et al: KIT Extracellular and Kinase Domain Mutations in G.I. Stromal Tumors. Am J Pathol 2000; 156: 791-795

23.  Heinrich M.C., Corless C.L., Demetri G.D., et al.: Kinase Mutations and Imatinib Response in Patients with Metastatic Gastrointestinal Stromal Tumor. J Clin Oncol 2003; 21: 4342-4349

24.  Corless C.L., Fletcher J.A., Heinrich M.C. Biology of Gastrointestinal Stromal Tumors J Clin Oncol 2004; 22: 3813-3825

25.  Lasota J., Wozniak A., Sarlomo-Ricala M., et al.: Mutations in Exon 9 and 13 of KIT Gene Are Rare Events in Gastrointestinal Stromal Tumors. A study of 200 cases. Am J Pathol 2000; 157: 1091-1095

26.  Hirota S., Nishida T., Isozaki K., et al.: Gain- of- Function Mutation at the Extracellular Domain of KIT in Gastrointestinal Stromal Tumors. J Pathol 2001; 193: 505-510

27. Antonescu C.R., Sommer G., Sarran L., et al.: Association of KIT Exon 9 Mutations with Nongastric Primary Site and Aggressive Behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9: 3329-3337

28.  Kinoshita K., Isozaki K., Hirota S., et al.: C-Kit Gene Mutation at Exon 17 or 13 is Very Rare in Sporadic Gastrointestinal Stromal Tumors. J Gastroenterol Hepatol 2003; 18: 147-151

29.  Hirota S., Ohashi A., Nishida T., et al: Gain-of-Function Mutations of Platelet-Derived Growth Factor Receptor Alpha in Gastrointestinal Stromal Tumors. Gastroenterology  2003; 125: 660-667

30. Corless C.L., Schroeder A., Griffith D, et al.: PDGFRA Mutations in Gastrointestinal Stromal Tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364

31. Agaimy A., Terracciano L.M., Dirnhofer S., et al.: V600E BRAF Mutations Are Alternative Early Molecular Events in a Subset  of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors. J Clin Pathol 2009; 62: 613-616

32.  Rubin P.B. Gastrointestinal Stromal Tumours: an update. Histopathology 2006; 48: 83-96

33. Grady W.M.: GISTs: The Revolution Continues (Editorials). Gastroenterology  2003; 125: 967-978

34. Berman J., and O’Leary T.J.: Gastrointestinal Stromal Tumors Workshop. Hum Pathol 2001; 32: 578-582

35. De Matteo R.P., Heinrich M.C., El-Rifal W.M., Demetri G.: Clinical Management of Gastrointestinal Stromal Tumors: Before and After STI-571. Hum Pathol 2002; 33: 466-477

36. Fletcher C.D.M., Berman J.J., Corless C. et al: Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach. Hum Pathol 2002; 33: 459-465

37. Goettsch W.G., Bos S.D., Breekveldt-Postma N., et al.: Incidence of Gastrointestinal Stromal Tumours is Underestimated: results of a nation-wide study. Eur J Cancer 2005; 41: 2868-2872

38. Nilsson B., Bümming P., Meis-Kindblom J.M., et al.: Gastrointestinal Stromal Tumors: the incidence, prevalence, clinical course, and prognostication in the preimanitib mesylate era—a population-based study in western Sweden. Cancer 2005; 15: 821-829

39. Emory T.S., Sobin L.H., Lukes L. et al: Prognosis of Gastrointestinal Smooth Muscle (Stromal) Tumors: Dependence on Anatomic Site. Am J Surg Pathol 1999;23: 82-87

40. Goldblum J.R., Appelman H.D.: Stromal Tumors of the Deuodenum: A Histologic and Immunohistochemical Study of 20 Cases. Am J Surg Pathol 1995; 19: 71-80

41. Tworek J.A., Appelman H.D., Singleton T.P. et al: Stromal Tumors of the Jejunum and Ileum. Mod Pathol 1997; 10: 200-209

42. Tworek J.A., Goldblum J.R., Weiss S.W. et al: Stromal Tumors of the Abdominal Colon: A Clinicopathologic Study of 20 Cases. Am J Surg Pathol 1999; 23: 937-945

43. Tworek J.A., Goldblum J.R., Weiss S.W. et al: Stromal Tumors of the Anorectum: A Clinicopathologic Study of 22 Cases. Am J Surg Pathol 1999; 23: 946-954

44. Miettinen M., Sarlomo-Rikala M., Sobin L.H. et al: Esophageal Stromal Tumors: A Clinicopathologic, Immunohistochemical and Molecular Genetic Study of 17 Cases and Comparison with Esophageal Leiomyomas and Leiomyosarcomas. Am J Surg Pathol 2000; 24: 211-222 

45. Miettinen M., Monihan J.M., Sarlomo-Rikala M. et al: Gastrointestinal Stromal Tumors/Smooth Muscle Tumors (GISTs) Primary in the Omentum and Mesentery: Clinicopathologic and Immunohistochemical Study of 26 Cases. Am J Surg Pathol 1999; 23: 1109-1118

46. Reith J.D., Goldblum J.R., Lytes R.H.: Extragastrointestinal (soft tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome. Mod Pathol 2000; 13: 577-585

47.  Weiss S.W., Goldblum J.R.: Extragastrointestinal Stromal Tumors. In Weiss S.W., Goldblum J.R. (eds): Enzinger and Weiss soft tissue tumors, 4th ed. St Louis,MO,Mosby, 2001,pp 749-768

48. Ortiz-Hidalgo C., de Leon Bojorge B., Albores-Saavedra J.: Stromal Tumors of the Gallbladder with Phenotype of Interstitial Cells of Cajals. A Previously Unrecognized Neoplasm. Am J Surg Pathol 2000; 24: 1420-1423

49. Lasota J., Carlson J.A., Miettinen M.: Spindle Cell Tumor of the Urinary Bladder Serosa with Phenotypic and Genotypic Features of G.I.Stromal Tumors. Arch Pathol Lab Med 2000; 124: 894-897 

50. Miettinen M., Sobin L.H.: Gastrointestinal Stromal Tumors in the Appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 2001; 25: 1433-1437

51. Daum O., Klecka J., Ferda J., et al.: Gastrointestinal Stromal Tumor of the Pancreas: case report with documentation of KIT gene mutation. Virchows Arch. 2005; 446: 470-472

52.  Thomas R.M., Sobin L.H.: Gastrointestinal Cancer Incidence and Prognosis by Histologic Type, SEER population-based data 1973-1987.Cancer 1987; 75: 154-170

53. De Matteo R.P., Lewis J.J., Leung D., et al.: Two Hundred Gastrointestinal Stromal Tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58

54. Durham M.M.,Gow K.W., Shehata B.M. et al: Gastrointestinal Stromal Tumors Arising from Stomach: A report of three children. J Pediatr Surg 2004; 39: 1495-1499

55. Cheung M.C., Zhuge Y., Yang R., Koniaris L.G.: Disappearance of Racial Disparities in Gastrointestinal Stromal Tumor Outcomes. J Am Coll Surg 2009; 209: 7-16

56. Gasparotto D., Rossi S., Bearzi I et al.: Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An underestimated entity. Clin Cancer Res 2008; 14: 5715-5721

57. Arnogiannaki N., Martzoukou I., Kountourakis P. et al.: Synchronous Presentation of GISTs and Other Primary Neoplasms: A Single Center Experience. In vivo 2010, 24: 109-116

58. Nishida T., Hirota S., Tanigushi M et al: Familial Gastrointestinal Stromal Tumors with Germline Mutation of the Kit Gene. Nat Genet 1998; 19: 323-324

59. Hirota S., Nishida T., Isozaki K. et al: Familial Gastrointestinal Stromal Tumors Associated with Dysphagia and Novel Type Germline Mutation Of KIT Gene. Gastroenterology  2002; 122: 1493-1499

60. Maeyama H., Hidaka E., Ota H. et al: Familial Gastrointestinal Stromal Tumors wit Hyperpigmentation: Association with a germline mutation of the c-kit. Gastroenterology 2001; 120: 210-215

61. O’Brien P., Kapusta L., Dardick I. et al: Multiple Familial Gastrointestinal Autonomic Nerve Tumors and Small Intestinal Neuronal Dysphagia. Am J Surg Pathol 1999; 23: 198-204

62. Hirota S., Okazaki T., Kitamura Y. et al: Multiple Familial Gastrointestinal Autonomic Nerve Tumors with Hyperplasia of Intestinal Cells of Cajals is Germline Mutation of the c-Kit Gene. Am J Surg Pathol 2000; 24: 326-327

63.  Isozaki K., Terris B., Belghiti J., et al: Germline Activating Mutation in the Kinase Domain of Kit Gene in Familial Gastrointestinal Stromal Tumors. Am J Surg Pathol 2000; 157: 1581-1585

64. Li F.P., Flecher J.A., Heinrich M.C. et al: Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred. J Clin Oncol 2005; 23: 2735-2743

65. Chompret A., Kannengiesser C., Barrois M. et al: PDGFRA Germline Mutation in a Family with Multiple Cases of Gastrointestinal Stromal Tumors. Gastroenterology 2004; 126: 318-321

66. Beghini A., Tibiletti M.G., Roversi G. et al.: Germline Mutation in the Juxtamembrane Domain of the Kit Gene in a Family with Gastrointestinal Stromal Tumors and Urticaria Pigmentosa. Cancer 2001; 92: 657-662

67. Zoller M.E., Rembeck B., Oden A. at al: Malignant and Benign Tumors in Patients with Neurofibromatosis Type I in a Defined Swedish Population. Cancer 1997; 79: 2125-2131

68. Min K.W., Balaton A.J.: Small Intestinal Stromal Tumors with Skeinoid Fibers in Neurofibromatosis: Report of  four cases with ultrastructural study of skeinoid fibers from paraffin blocks. Ultrastruct Pathol 1993; 17: 307-314

69.  Takasawa Y., Sakurai S., Sakuma Y., et al: Gastrointestinal Stromal Tumors of Neurofibromatosis Type I (Von Recklinhausen’s disease). Am J Surg Pathol 2005; 29: 755-763

70.  Yantiss R.K., Rosenberg A.E., Sarran I. et al: Multiple Gastrointestinal Stromal Tumors in Type I Neurofibromatosis: a pathognomonic and molecular study. Mod Pathol 2005; 18: 475-484

71.  Carney J.A., Sheps S.G., Go V.L.W., Gordon H.: Triad of Gastric Leiomyosarcoma, Functioning Extra-adrenal Paragagglioma and Pulmpnary Chondroma. N Engl J Med 1977; 296: 1517-1518

72. Carney J.A.: The Triad of Gastric Epithelioid Leiomyosarcoma, Functioning Extra-adrenal Paraganglioma and Pulmonary Chondroma. Cancer 1979; 43: 374-382

73.  Carney J.A.: Gastric Stromal Sarcoma, Pulmpnary Chondroma and Extra-adrenal Paragagglioma (Carney Triad): Natural history, adreno-cortical component, and possible familial occurrence. Mayo Clin Proc 1999; 74: 543-552

74. Price V.E., Zielenska M., Chilton-MacNeil S. et al: Clinical and Molecular Characteristics of Pediatric Gastrointestinal Stromal Tumors (GISTs). Pediatr Blood Cancer 2005; 45: 20-24

75. Prakash S., Sarran L., Socci N. et al: Gastrointestinal Stromal Tumors in Children and Young Adults: a clinicopathologic, molecular and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 2005; 25: 179-189

76. Diment J., Tamborini E., Casali P. et al: Carney Triad: case report and molecular analysis of gastric tumor. Hum Pathol 2005; 36: 112-116

77. Carney J.A., Stratakis C.A.: Familial Paragagglioma and gastric Stromal Sarcoma: A new syndrome distinct from the Carney triad. Am J Med Genet 2002; 108: 132-139

78.  Stratakis C.A., Carney J.A.: The Triad of Paragagglioma, Gastric Stromal Tumors and Pulmonary Chondromas (Carney-Stratakis Sydrome): Molecular genetics and clinical implications. J Int Med 2009; 266: 43-52

79. Alrashdi I., Bano G., Maher E.R., Hodgson S.V. Carney Triad Versus Carney-Stratakis Syndrome: Two cases which illustrate the difficulty in distinguishing between these two conditions in individual patients. Fam Cancer 2010; 9: 443-447

80. Lau S., Tam K.F., Kam C.K. et al.: Imaging of Gastrointestinal Stromal Tumors (GIST). Clin Radiol 2004; 59: 487-498

81.  Nguyen V.H., Taylor A.: Gastrointestinal Stromal Tumors Leiomyoma /Leiomyo-sarcoma. 2008;

82.  Pidhorecky I., Cheney R.T., Kraybill W.G., Gibbs J.F.: Gastrointestinal Stromal Tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-712

83. Poylin V.Y., Fisher J.E. Small Bowel Tumors: In Cameron J.L.. Current Surgical Therapy. 9th ed., Philadelphia, Mosby Inc., 2008, sect3, ch.32

84. Ghanem N., Altehoefer C., Furtwangler A. et al.: Computed Tomography in Gastrointestinal Stromal Tumors. Eur Radiol 2003; 13: 1669-1678

85.  Tateishi U., Hasegawa T., Satake M., Moriyana N.: Gastrointestinal Stromal Tumors. Correlation of Computed Tomography Findings with Tumor Grade and Mortality. J Comput Assist Tomogr 2003; 27: 792-798

86.  Miller F.H., Hwang C.M. An Initial Experience Using Helical CT Imaging to Detect Obscure Gastrointestinal Bleeding. J Clin Imaging 2004; 28: 245-251

87. Maglinte D.D., Siegelman E.S., Kelvin F.M.: MR-Enteroclysis: The future of small-bowel imaging. Radiology 2000; 215: 639-641

88.  Moawad F.J., LaRock T.R., Biondi M.C. et al.: A case of Obscure Gastrointestinal Bleeding Secondary to a Small Bowel Gastrointestinal Stromal Tumor Detected by Magnetic Resonance Enterography. Medscape J Med 2008; 10: 263

89. Tada M., Misaki F., Keiichi K.: Pediatric Enteroscopy with a Sonde-type Small Intestinal Fiberscope (SSIF-type VI). Gastrointest Endosc 1983; 29: 44-47

90. Shidu R., Sanders D.S., McAlindon M.E., Thomson M.: Capsule Endoscopy and Enteroscopy: modern modalities to investigate the small bowel in paediatrics. Arch Dis Child 2008; 93: 154-159

91. Foutch P.G., Sawyer R., Sanowski R.A.: Push-enteroscopy for Diagnosis of Patients with Gastrointestinal Bleeding of Obscure Origin. Gastrointest Endosc 1990; 36: 337-341

92. Nguyen N.Q., Rayner C.K., Shoeman M.N.: Push Enteroscopy Alters Management in a Majority of Patients with Obscure Gastrointestinal Bleeding. J Gastrointest Hepatol 2005; 20: 716-721.

93. Iddam G., Meron G., Glukhovski A., Swain P.: Wireless Capsule Endoscopy. Nature 2000; 405: 417

94.  Yamamoto H., Sekine Y., Sato Y., et al.: Total Enteroscopy with a Non-surgical Steerable Double-balloon Method. Gastrointest Endosc 2001; 53: 216-220

95.  Jonnalagada S., Prakash C.: Intestinal Strictures Can Impede Wireless Capsule Enteroscopy. Gastrointest Endosc 2003; 57: 418-420

96.  Barkin J., Friedman S.: Wireless Capsule Endoscopy Requiring Surgical Intervention: The world’s experience (abstract). Am J Gastrointerol 2002; 97: A907. Cited in Shidu R., Sanders D.S., McAlindon M.E., Thomson M.(65)

97. Rastogi A., Schoen R.E., Slivka A.: Diagnostic Yield and Clinical Outcomes of Capsule Endoscopy. Gastrointest Endosc 2004; 60: 959-964

98. Costamagna G., Shah S.K., Riccioni M.E. et al.: A Prospective Trial Comparing Small Bowel Radiographs and Video Capsule Endoscopy for Suspected Small Bowel Disease. Gastroenterology 2002; 123: 999-1005

99.  Lewis B., Swain P.: Capsule Endoscopy in the Evaluation of Patient Suspected Small Intestinal Bleeding. Gastrointest Endosc 2002; 56: 349-353

100. Scapa E., Jacobs H., Lewkowicz S. Et al.: Initial Experience of Wireless Capsule Endoscopy for Evaluating Occult Gastrointestinal Bleeding and Suspected Small Bowel Pathology. Am J Gastroenterol 2002; 97: 2276-2279

101. Mylonaki M., Fritscher-Ravens A., Swain P.: Wireless Capsule Endoscopy: A comparison with push-enteroscopy in a patient with gastroscopy and colonoscopy negative gastrointestinal bleeding. Gut 2003; 52: 1122-1126

102. Adler D.G., Knipschield M., Gostout C.: A Prospective Comparison of Capsule Endoscopy and Push-Enteroscopy in Patients with GI Bleeding of Obscure Origin. Gastrointest Endosc 2004; 59: 492-498

103. Kraus K., Hollerbach S., Pox C.: Diagnostic Utility of Capsule Endoscopy in Occult Gastrointestinal Bleeding. Dtsch med Wochenschr 2004; 129: 1369-1374

104. Shidu R., Sanders D.S., McAlindon M.E. Gastrointestinal Capsule Endoscopy: from tertiary centers to primary care. BMJ 2006; 332: 528-531

105. Cobrin G.M., Pittman R.H., Lewis B.L.: Increased Diagnostic Yield of Small Bowel Tumors with Capsule Endoscopy. Cancer 2006; 107: 22-27

106. Estevez E., Gonzalez-Conde B., Vazquez-Iglesias J.L. et al.: Incidence of Tumoral Pathology According to Study Using Capsule Endoscopy for Patients with Obscure Gastrointestinal Bleeding. Surg Endosc 2007; 21: 1776-1780

107. Yamamoto H., Kita H., Sunada K., et al.: Clinical Outcomes of Double-balloon Endoscopy for the diagnosis and Treatment of Small-intestinal Diseases. Clin Gastroenterol Hepatol 2004; 2: 1010-1016

108. Di Caro S., May A., Heine D.G.N., et al.: The European Experience with Double-balloon Enteroscopy: indications, methodology, safety and clinical impact. Gastrointest Endosc 2005; 62: 545-550

109. May A., Nachbar L., Ell C.: Double-Balloon Enteroscopy (push and pull enteroscopy) of the Small Bowel: feasibility and diagnostic and therapeutic yield in patients with suspected small bowel disease. Gastrointest Endosc 2005; 62: 62-70

110. May A., Nachbar L., Schneider M., Ell C.: Prospective Comparison of Push Enteroscopy and Push-and-pull Enteroscopy in Patients with Suspected Small-bowel Bleeding. Am J Gastroenterol 2006; 101: 2016-2024

111. Heine G.D.N., Hadithi M., Groenen M.J.M., et al.: Double-balloon Enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small bowel disease. Endoscopy 2006; 38: 42-48

112. Mehdizadeh S., Ross A., Gerson L., et al.: What is the Learning Curve Associated with Double-balloon Endoscopy? Technical details and early experience in 6 U.S. tertiary care centers. Gastrointest Endosc 2006; 64: 740-750

113. Sun B., Rajan E., Cheng S. et al.: Diagnostic Yield and therapeutic Impact of Double-Balloon Enteroscopy in a Large Cohort of Patients with Obscure Gastrointestinal Bleeding. Am J Gastroenterol 2006; 101: 2011-2015

114. Gross S.A., Stark M.A.: Initial Experience with Double-balloon Enteroscopy at a U.S. Center. Gastrointest Endosc 2008; 67: 890-897

115. Tsujikawa T., Saitoh Y., Andoh A. et al.: Novel Single-Balloon Enteroscopy for Diagnosis and Treatment of the Small Intestine: Preliminary experiences. Endoscopy 2008; 40: 11-15

116. Akerman P.A., Cantero D., Avila J et al.: The Spiral EndoscopyExperience in 101 Consecutive Patients: safety and efficacy using the discovery SB. Gastrointest Endosc 2008; 67: AB92-AB93

117. Tio T.L., Tytgat G.N.J., den Hartog Jager F.C.A. : Endoscopic Ultrasonography for the Evaluation of Smooth Muscle Tumors in the Upper Gastrointestinal Tract: an experience with 42 cases. Gastrointest Endosc 1990; 36: 342-350

118. Chak A., Canto M.I., Rosch T. et al.: Endosonographic Differentiation of Benign and Malignant Stromal Cell Tumors. Gastrointest Endosc  1997; 45: 468-473

119. Palazzo L., Landi B., Cellier C., et al.: Endosonographic Features Predictive of Benign and Malignant Gastrointestinal Stromal  Cell Tumors. Gut  2000; 46: 88-92

120. Kim G. H., Park D.Y., Kim S. et al.: Is it Possible to Differentiate Gastric GISTs from Gastric Leiomyomas by EUS? World J Gastroenterol 2009; 15: 3376-3381

121. Rösch T., Kapfer B., Will U. et al.: Accuracy of Endoscopic Ultrasonography in Upper Gastrointestinal Submucosal Lesions: a prospective multicenter study. Scand J Gastroenterol 2002;37: 856-862

122. Belloni M., De Fiori E., Mazzarol G. et al.: Endoscopic Ultrasound and Computed Tomography in Gastric Stromal Tumors. Radiol Med 2002; 103: 65-73

123. Ha C.H., Shach R., Chen J., et al.: Diagnosis and Management of GI Stromal Tumors by EUS-FNA: a survey of opinions and practices of endosographers. Gastrointest Endosc 2009; 69: 1039-1044

124. Hunt G.C., Smith P.P., Faigel D.O.: Yield of Tissue Sampling for Submucosal Lesions Evaluated by EUS. Gastrointest Endosc 2003; 57: 68-72

125. Philiper M., Hollerbach S., Gabbert H.E. et al.: Prospective Comparison of Endoscopic Ultrasound-guided Fine-needle Aspiration and Surgical Histology in Upper Gastrointestinal Submucosal Tumors. Endoscopy 2010; 42: 300-305

126. Hollerbach P.M., Gabbert H.E., Heikaus S., et al.: Prospective Comparison of Endoscopic Ultrasound-Guided Fine-Needle Aspiration and Surgical Histology in Upper Gastrointestinal Submucosal Tumors. Endoscopy 2010; 42: 300-305

127. Hwang J.H., Rulyak S.D., Kimmey M.B.: American Gastroenterological Association Institute Technical Review on the Management of Gastric Subepithelial Masses. Gastroenterology 2006; 130: 2217-2228

128. Akahoshi K., Sumida Y., Matsui N., et al.: Preoperative Diagnosis of Gastrointestinal Stromal Tumors by Endoscopic Ultrasound-guided Fine-needle Aspiration. W J Gastroenterol 2007; 13: 2077-2082

129. Akahoshi K., Oya M.: Gastrointestinal Stromal Tumor of the Stomach: How to manage. W J Gastroenterol  2010; 2: 271-277

130. Gerke H., Rizk M.K., Vanderheyden A.D., Jensen C.S.: Randomized Study Comparing Endoscopic Ultrasound-guided Trucut Biopsy and Fine Needle Aspiration with High Suction. Cytopathology 2010; 21: 44-51

131. AlHaddat M., DeWitt J.: Editorial: EUS-guided Sampling of Suspected GI Mesenchymal Tumors: cells, cores or a combination? Gastrointest Endosc 2009; 69: 1224-1227

132. Ando N., Goto H., Niwa Y., et al.: The Diagnosis of GI Stromal Tumors with EUS-guided Fine-needle Aspiration with Immunohistochemical Analysis. Gastrointest Endosc 2002; 55: 37-43

133. Aithal G.P., Anagnostopoulos G.K., Tam W., et al.: EUS-guided Tissue-sampling: Comparison of ‘’dual sampling’’ (Trucut biopsy plus FNA) with ‘’Sequential sampling’’ (Trucut biopsy and then FNA as required). Endoscopy 2007; 30: 725-730

134. Jenssen C., Diedrich C.F.: Endoscopic Ultrasound-guided Fine-needle Aspiration Biopsy in Gastroenterology- An Overview. Best Practice Res Clin Gastroenterol 2009; 23: 743-759

135. Gomes A.L., Bardales R.H., Milanezi F., et al.: Molecular Analysis of c-Kit and PDGFRA in GISTs Diagnosed by EUS. Am J Clin Pathol 2007; 127: 89-96

136. Alavi A., Dann R.W., Baum S., et al.: Scintigraphic Detection of Acute Gastrointestinal Bleeding. Radiology 1977; 124: 753-756

137. Baum S., Athanasoulis C.A., Waltman A.C., et al.: Gastrointestinal Hemorrhage. II. Angiographic Diagnosis and Control. Adv Surg 1973; 7: 149-198

138. Rollins E.S., Picus D., Hicks M.E., et al.: Angiography is Useful in Detecting the Source of Chronic Gastrointestinal Bleeding of Obscure Origin. Am J Roentgenol 1991; 156: 385-388

139. Sheedy F.P. II., Fulton R.E., Atwell D.T.: Angiographic Evaluation of Patients with Chronic Gastrointestinal Bleeding. Am J Roentgenol Radium Ther Nucl Med 1975; 123: 338-347

140. Bloomfeld R.S., Smith T.P., Schneider A.M., et al.: Provocative Angiography in Patient with Gastrointestinal Bleeding of Obscure Origin. Am J Gastroenterol 2000; 95: 2807-2812

141. Shetzline M.A., Suhocki P., Dash R., Rockey D.C.: Provocative Angiography in Obscure Gastrointestinal Bleeding. South Med J 2000; 93: 1205-1208

142. Delgado Bolton R.C., Izarduy L.P., Carreras Delgado J.L.: Positron Emission Tomography and Positron Tomography/Computed Tomography in the Evaluation of Response to Chemotherapy. Cancer Chemother Rev 2008; 3: 77-86

143. Demetri G,D., Benjamin R., Blanke C.D. et al.: NCCN Task Force Report: Optimal management of patients with gastrointestinal stromal tumor (GIST)-expansion and update of NCCN clinical practice guidelines. JNCCN 2004; 2(suppl 1): S1-S26

144. Hasegawa T., Matsuno Y., Shimoda et al.: Gastrointestinal Stromal Tumors: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-676

145. De Silva C.M., Reid R.: Gastrointestinal Stromal Tumors (GIST): C-Kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9: 13-19.

146. Μiettinen M., Sobin L.H., Lasota J. Gastrointestinal Stromal Tumors of the Stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68

147. Wasag B., Debiec-Rychter M., Pauwels P. Et al.: Differential Expression of KIT/PDGFRA Mutant Isoforms in Epithelioid and Mixed Variants of Gastrointestinal Stromal Tumors Depends Predominantly on the Tumor Site. Mod Pathol 2004; 17: 889-894

148. Wieczorek T.J., Faquin W.C., Rubin B.P. et al.: Cytologic Diagnosis of Gastrointestinal Stromal Tumor with Emphasis on the Differential Diagnosis with Leiomyosarcoma. Cancer 2001; 93: 276-287

149. Suster S., Fletcher C.D.: Gastrointestinal Stromal Tumors with Prominent Signet-ring Cell Features. Mod Pathol 1996; 9: 609-613

150. Shek T.W., Luk I. S., Loong F. Et al.: Inflammatory Cell-rich Gastrointestinal Autonomic Nerve Tumor. An expansion of its histologic spectrum. Am J Surg Pathol 1996; 20: 325-331

151. Min K.W.: Small Intestinal Stromal Tumors with Skeinoid Fibers. Clinicopathological, immunohistochemical, and ultrastructural investigations. Am J Surg Pathol 1992; 16: 145-155

152. Yantiss R.K., Rosenberg A.E., Selig M.K., et al.: Gastrointestinal Stromal Tumors: an ultrastructural study. Int J Surg Pathol 2002; 10: 101-113

153. Lee J.R., Joshi V., Griffin J.W.,Jr, et al.: Gastrointestinal Autonomic Nerve Tumor: immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001; 25: 979-987

154. Miettinen M., Virolainen M, Sarlomo-Ricala M.: Gastrointestinal Stromal Tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207-216

155. Sarlomo-Rikala M., Kovatich A.J., Barucevicius A. Et al.: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734

156. Medeiros F., Corless C.L., Duencing A. et al.: KIT-negative Gastrointestinal Stromal Tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28: 889-894

157. Debiec-Rychter M., Wasag B., Stul M et al.: Gastrointestinal Stromal Tumors (GISTs) negative for KIT (CD117 antigen) Immunoreactivity. J Pathol 2004; 202: 430-438

158. Miettinen M., Sobin L.H., Sarlomo-Rikala M.: Immunohistochemical Spectrum of GISTs at Different Sites and their Differential Diagnosis with Reference to CD117(KIT). Mod Pathol 2000; 13: 1134-1142

159. Miettinem M., Sarlomo-Ricala M., Lasota J.: KIT expression in Angiosarcomas and Fetal Endothelial Cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol 2000; 13: 536-541 

160. West R.B., Corless C.L., Chen X., et al.: The Novel Marker, DOG1, is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrispective of KIT or PDGFRA Mutation Status. Am J Pathol 2004; 165: 107-113

161. Espinoza I., Lee C.H., Kim M.K., et al.: A Novel Monoclonal Antibody Against Dog I is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors. Am J Surg Pathol 2008; 32: 210-218

162. Liegl B., Hornick J.L., Corless C.L., Fletcher C.D.: Monoclonal Antibody DOG 1.1 Shows High Sensitivity than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes. Am J Surg Pathpl 2009; 33: 437-446

163. Blay P., Astudillo A., Buesa J.M., et al.: Protein Kinase C Theta is Highly Expressed in Gastrointestinal Stromal Tumors but not in Other Mesenchymal Neoplasias. Clin Cancer Res 2004; 10: 4089-4095

164. Bragio D.A., Romano S., Small I.A., et al.: Protein Kinase C θ (PKCθ) Expression as a Potential Diagnostic Marker for KIT-negative GIST. J Clin Oncol 2009; 27:15s(abstr 10561)

165. Miettinen M., Sarlomo-Ricala M., Sobin L.H, Lasota J.: Gastrointestinal Stromal Tumors and Leiomyosarcomas in the Colon: a clinicopathologic, immunohistochemical, molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24: 1339-1352

166. Sarlomo-Rikala M, Miettinen M.: Gastric Schwannoma-a clinicopathological analysis of six cases. Histopathology 1995; 27: 355-360

167. Miettinen M., Shekitka K.M., Sobin L.H.: Schwannomas in the Colon and Rectum: a clinicopathologic and immunohistchemical study of 20 cases. Am J Surg pathol 2001; 25: 846-855

168. Hasegawa T., Yang P., Kagawa N., et al.: CD34 Expression by Inflammatory Fibroid Polyps of the Stomach. Mod Pathol 1997; 10: 451-456

169. Lasota J., Wang Z-F., Sobin L.H., Miettinen M.: Gain-Of-Function PDGFRA Mutations, Earlier Reported in Gastrointestinal Stromal Tumors, Are Common in Small Intestinal Inflammatory Fibroid Polyps. A study of 60 bcases. Mod Pathol 2009; 22: 1049-1056 

170. Pantanowitz L., Antonioli D.A., Pinkuw G.S. et al.: Inflammatory Fibroid Polyps of the Gastrointestinal Tract: evidence for a dendritic cell origin. Am J Surg Pathol 2004; 28: 107-114

171. Yantiss R.K., Spiro I.J., Compton C.C., Rosenberg A.E.: Gastrointestinal Stromal Tumors Versus Intra-abdominal Fibromatosis of the Bowel Wall. Am J Surg Pathol 2000; 24: 947-957

172. Hornick J.L., Fletcher C.D.: Immunohistochemical Staining  for KIT(CD117) in Soft Tissue Sarcomas is Very Limited in Distribution. Am J Clin Pathol 2002; 117: 188-193

173. Miettinen M.: Are Desmoid Tumors Kit Positive [letter]? Am J Surg Pathol 2001; 25: 549-550

174. Lukas D.R., Al-Abbadi M., Tabaczka P., et al.: C-Kit Expression in Desmoid Fibromitosis: Comparative Immunohistochemical Evaluation of Two Commersial Antibodies. Am J Clin Pathol 2003;119: 339-345

175. Montgomery E., Torbenson M.S., Kaushal M., et al.: Beta-Catenin Immunohistochemistry Separates Mesenteric Fibromatosis from Gastrointestinal Stromal Tumors and sclerosing Mesenteritiw. Am J Surg Pathol 2002; 26: 1296-1301

176. Carlson J.W., Fletcher C.D.: Immunohistochemistry for Beta-Catenin in the Differential Diagnosis of Spindle Cell Lesions: analysis of a series and review of the literature. Histopathology 2007; 51: 509-514

177. Miettinen M., Kopczynski J., Makhlouf H.R., et al.: Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical , and Molecular Genetic Study of 167 Cases. Am J Surg Pathol 2003; 27: 625-641

178. Appelman H., Helwig E.B.: Cellular Leiomyomas of the Stomach in 49 Patients. Arch Pathol Lab Med 1977;101: 373-377

179. Ueyama T., Guo K.J., Hashimoto H., et al.: A Clinicopathologic and Immunohistochemical Study of Gastrointestinal Stromal Tumors. Cancer 1992; 69: 947-955

180. Brainard J.A., Goldblum J.R.: Stromal Tumors of the Jejunum and Ileum: A clinicopathologic study of 39 cases. Am J Surg Pathol 1997; 21: 407-416

181. Miettinen M., Furlong M., Sarlomo-Rikala M., et al.: Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and the Anus: A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25: 1121-1133

182. Ranchod M., Kempson R.L.: Smooth Muscle Tumors of the Gastrointestinal Tract and Retroperitoneum: a pathologic analysis of 100 cases. Cancer 1977; 39: 255-262

183. Evans H.L.: Smooth Nuscle Tumors of the Gastrointestinal Tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56: 2242-2250

184. Franquemont D.W.: Differentiation and Risk Assessment of Gastrointestinal Stromal Tumors. Am J Clin Pathol 1995; 103: 41-47 

185. De Saint Aubain Somerhausen N., Fletcher C.D.M.: Gastrointestinal Stromal Tumors: An update. Sarcoma 1998; 2: 133-141

186. Singer S., Rubin B.P., Lux M.L., et al.: Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. J Clin Oncol 2002; 20: 3898-3905

187. Νg Ε.Η., Pollock R.E., Munsell M.F., et al.: Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas: implications for surgical management and staging. Ann Surg 1992; 215: 68-77  

188. Ernst S.I., Hubbs A.E., Przygodzki R.M. et al.: KIT Mutation Portends Poor Prognosis in Gastrointestinal Stromal/Smooth Muscle Tumors. Lab Invest 1998; 78: 1633-1636

189. Lasota J., Jasinski M., Sarlomo-Ricala M., et al.: Mutations in Exon 11 of c-kit Occur Preferentially in Malignant Versus Benign Gastrointestinal Stromal Tumors and dont Occur in Leiomyomas or Leiomyosarcomas. Am J Pathol 1999; 154: 53-60

190. Taniguchi M., Nishida T., Hirota S. et al: Effect of the c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors. Cancer Res 1999; 59: 4297-4300

191. Rudolph P., Gloeckner K., Parwaresch R., et al.: Immunophenotype, DNA ploidy, and Biological Behavior of Gastrointestinal Stromal Tumors: a multivariate clinicopathologic study. Hum Pathol 1998; 29: 791-800

192. Panizo-Santos A., Sola I., Vega F., et al.: Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: role of the cell proliferation and cell cycle regulatory  proteins. Int J Surg Pathol 2000; 8: 133-144

193. Al-Bozom I.A.: p53 Expression in gastrointestinal Stromal Tumors. Pathol Int 2001; 51: 519-523

194. Cunnigham R.E., Abbondanzo S.L., Chu W.S., et al.: Apoptosi, Bcl-2 Expression, and p53 Expression in Gastrointestinal Stromal/Smooth Muscle Tumors. Appl Immunohistochem Mol Morphol 2001; 9: 19-23

195. Schneider-Stock R., Boltze C., Lasota J., et al.: High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors. J Clin Oncol 2003; 21: 1688-1697

196. Takahashi R., Tanaka S., Kitadai Y., et al.: Expression of vascular Endothelial Growth Factor and Angiogenesis in Gastrointestinal Stromal Tumors of the Stomach. Oncology 2003; 64: 266-274 

197. Amin M.B., Ma C.K., Linden M.D., et al.: Prognostic Value of Proliferating Cell Nuclear Antigen Index in Gastric Stromal Tumors. Correlation with Mitotic Count and Clinical Course. Am J Clin Pathol 1993; 100: 428-432

198. Kiyabu M.T., Bishop P.C., Parker J.W., et al.: Smooth Muscle Tumors of the Gastrointestinal Tract.Flow Cytometric Quantitation of DNA and Nuclear Antigent Content and Correlation with Histologic Grade. Am J Surg Pathol 1988; 12: 954-960.

199. Cooper P.N., Quirke P., Hardy G.J., et al.: A Flow Cytometric, Clinical and Histological Study of Stromal Neoplasms of the Gastrointestinal Tract. Am J Surg Pathol 1992; 16: 163-170

200. Pauser U., Schmedt auf der Günne N., Klöppel N., et al.: p53 Expression is Significantly Correlated wit High Risk of Malignancy and Epithelioid Differentiation in GISTs. An immunohistochemical analysis of 104 cases. BMC Cancer 2008; 8: 204 

201. Sakurai S., Fukayama M., Kaizaki Y et al.: Telomerase activity in Gastrointestinal Stromal Tumors. Cancer 1998; 83: 2060-2066

202. Günther T., Schneider-Stock R., Häckel C., et al.: Telomerase Activity and Expression of hTR in Gastrointestinal Stromal Tumors in Comparison with Extragastrointestinal Sarcomas.  Clin Cancer Res 2000; 6: 1811-1818

203. Kawai J., Kodera Y., Fujiwara M., et al.: Telomerase Activity as Prognostic Factor in Gastrointestinal Stromal Tumors of the Stomach. Hepatogastroenterology 2005; 52: 959-964

204. DeMatteo R.P., Shah A., Fong Y., et al.: Results of Hepatic Resection for Sarcoma Metastatic to Liver. Ann Surg 2001; 234: 540-547, discussion 547-548

205. Gottlieb J.A., Baker L.H., O’Bryan R.M., et al.: Adriamycin (NSC123127) Used Alone and in Combination for Soft Tissue and Bony Sarcomas. Cancer Chemother Rep Part 3. 1975; 6: 271-282

206. Trent J.C., Beach J., Burgess M.A., et al.: A Two-arm Phase II Study of Temozolomide in Patients with Advanced Gastrointestinal Stromal Tumors and Other Soft Tissue Sarcomas. Cancer 2003; 98: 2693-2699

207. Edmonson J.H., Ryan L.M., Blum R.H., et al.: Randomized Comparison of Doxorubicin Alone Versus Ifosfamide plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas. J Clin Oncol 1993; 11: 1269-1275

208. Plaat B.E., Hollema H., Molenaar  W.M., et al.: Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in clinicak outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-3220

209. Bilimoria M.M., Holtz D.J., Mirza N.Q. et al.: Tumor Volume as a Prognostic Factor for Sarcomatosis. Cancer 2002; 94: 2441-2446

210. Eilber F.C., Rosen G., Forchr C. et al.: Surgical Resection and Intraperitoneal Chemotherapy for Recurrent Abdominal Sarcomas. Ann Surg Oncol 1999; 6: 645-650

211. Mavligit G.M., Zukwiski A.A., Ellis L.M., et al.: Gastrointestinal Leiomyosarcoma Metastatic to the Liver. Durable Tumor Regression by Hepatic Chemoembolization Infusion with Cisplatin and Vinblastine. Cancer 1995; 75: 2083-2088

212. Mallucio M.A., Covey A. M., Schubert J. et al.: Treatment of Metastatic Sarcoma of the Liver with Bland Embolization. Cancer 2006; 107: 1617-1623

213. Katz S.C., DeMatteo R.P.: Gastrointestinal Stromal Tumors and Leiomyosarcomas. J Surg Oncol 2008; 97: 350-359

214.Van Oosterom A.T., Judson I., Verweij J., et al.: Safety and Efficacy of Imatinib (STI571) in Metastatic Gastrointestinal Stromal Tumours: A phase I study. Lancet 2001; 358: 1421-1423

215. Demetri G.D., von Mehren M., Blanke C.D., et al.: Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. N Engl J Med 2002; 347: 472-480

216. Verweij J., Casali P.G., Zalcberg J., et al.: Progression-free Survival in Gastrointestinal Stromal Tumors with High-dose Imatinib: Randomised trial. Lancet 2004; 364: 1127-1134

217. DeMatteo R., Maki R.G., Singer S., et al.: Results of Tyrosine Kinase Inhibitor Therapy followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Ann Surg 2007; 245: 347-352

218. Van Glabbeke M., Verweij J., Casali P.G., et al.: Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organization for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005; 23: 5795-5804

219. Antonescu C.R., Besmer P., Guo T., et al.: Aquired Resistance to Imatinib in Gastrointestinal Stromal Tumors Occurs Through Secondary Gene Mutation. Clin Cancer Res 2005; 11: 4182-4190

220. Debiek-Rychter M., Cools J., Dumez H., et al.: Mechanisms of Resistance to Imanitib Mesylate in Gastrointestinal Stromal Tumors and Activity of the PKC412 Inhibitor Against Imatinib-Resistant Mutants. Gastroenterology 2005; 128: 270-279

221. Prenen H., Cools J., Mentens N., et al.: Efficacy of the Kinase Inhibitor SU11248 Against Gastrointestinal Stromal Tumors Mutants Refractory to Imatinib Mesylate. Clin Cancer Res 2006; 12: 2622-2627

222. Demetri G., Desai J., Fletcher J. et al.: SU11248. A Multitargeted Tyrosine Kinase Inhibitor, Can Overcome Imatinib (IM) Resistance Caused by Diverse Genomic Mechanisms in Patients with Metastatic Gastrointestinal Stromal Tumor (GIST). J Clin Oncol 2004, ASCO Annual Meeting Proceedings (post meeting edition); 22,No 14S (July 15 Supplement), 3001

223. DeMatteo R.: Adjuvant Imatinib Mesylate in Patients with Primary High Risk Gastrointestinal Stromal Tumor (GIST) Following Complete Resection: Safety Results  from the U.S. Intergroup Phase II Trial ACOSOG Z9000. In ASCO 2005

224. Blackstein M.E., Blay J.Y., Corless C., et al.: Gastrointestinal Stromal Tumours: Consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20: 157-163

225. Choi H., Chamsangavej C., de Castro Faria S., et al.: CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A quantititative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619-1628

226. Stroszczynski C., Jost J., Reichardt P., et al.: Follow-up of Gastrointestinal Stromal Tumors (GIST) During Treatment with Imatinib Mesylate by Abdominal MRI. Eur Radiol 2005; 15: 2448-2456

227. Le Cesne A., Perol D., Ray-Coquard I., et al.: Interruption of Imanitib (IM) in GIST Patients with Advanced Disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of live (abstract 9031). J Clin Oncol 2005, ASCO Annual Meeting Proceeding; 23, No 16S, Part-I of II (June 1 supplement),9031

228. Casali P.G., Jost L., Reichardt P., et al.: Gastrointestinal Stromal Tumors: ESMO clinical recommendations for diagnosis, treatment and folow up. Ann Oncol 2009; 20 (suppl.4): 64-67

229. National Comprehensive Cancer Network. The NCCN Soft Tissue Sarcoma Clinical Practice Guidlines in Oncology (Version 1.2009I). National Comprehensive Cancer Network, PA, USA ,2009

230. Debiek-Rychter M., Sciot R., Le Cesne A., et al.: KIT Mutations and Dose Selection for Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors. Eur J Cancer 2006; 42: 1093-1103

231. Blay J. Y., Le Cesne A., Ray-Coquard I et al.: Prospective Multicentric Randomized Phase III Study of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyon 1 Year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113

232. Benjamin R.S., Choi H., Macapinlac H.A., et al.: We Should Desist Using RECIST, at Least in GIST. J Clin Oncol 2007; 25: 1760-1764

233. Blanke C.D., Demetri G.D., von Mehren M., et al.: Long-term Results from a Randomized Phase II Trial of Standard-Versus Higher-dose Imatinib Mesylate for Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. J Clin Oncol 2008; 26: 620-625

234. Hasan I., You Y. N., Shyyan R., et al.: Surgically Managed Gastrointestinal Stromal Tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15: 52-59

235. Blanke C.D., Rankin C., Demetri G.D., et al.: Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Tumors Expressing the KIT Receptor Tyrosine Kinase: S0033. J Clin Oncol 2008; 26: 626-632

236. Chen H., Pruit A., Nicol T., et al.: Complete Hepatic Resection of Metastases from Leiomyosarcoma Prolongs Survival. J Gastrointest Surg 1998; 2: 151-155

237. Bauer S., Hartmann J.T., de Witt M., et al.: Resection of Residual Disease  in Patients with Metastatic Gastrointestinal Stromal Tumors Responding to Treatment with Imatinib. Int J Cancer 2005; 117: 316-325

238. Bonvalot S., Eldweny H., Pechoux C.L., et al.: Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. Ann Surg Oncol 2006; 13: 1596-1603

239. Rutkowski P., Nowecki Z., Nyckowski P., et al.: Surgical Treatment of Patients with Initially Inoperable and/or Metastatic Gastrointestinal Stromal Tumors (GIST) During Therapy with Imatinib Mesylate. J Surg Oncol 2006; 93: 304-311

240. Hasegawa J., Kanda T., Hirota S., et al.: Surgical Interventions for Focal Progression of Advanced Gastrointestinal Stromal Tumors During Imatinib Therapy. Int J Clin Oncol 2007; 12: 212-217

241. Gronchi A., Fiore M., Miseli F., et al.: Surgery of Residual Disease Following Molecular-Targeted Therapy with Imatinib Mesylate in Advanced/Metastatic Gist. Ann Surg 2007; 245: 341-346 

242. Sym S. J., Ryu M.H., Lee J.L., et al.: Surgical Intervention Following Imatinib Treatment in Patients with Advanced Gastrointestinal Stromal Tumors (GISTs). J Surg Oncol 2008; 98: 27-33

243. Adenis A., Cassier P., Bui B.N., et al.: Does Interruption of Imatinib (IM) in Responding Patients After Tree Years of Treatment Inflyence of Outcome of Patients with Advanced GIST Included in the BFR14 Trial? J Clin Oncol 2008; 28(Suppl.), (abstr. 10522)

244. Raut C.P., Posner M., Desai J., et al.: Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment with Targeted Systemic Therapy Using Kinase Inhibitors. J Clin Oncol 2006; 24: 2325-2331

245. Eisenberg B.L., Judson I.: Surgery and Imanitib in the Management og GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11: 465-475

246. Radiation Therapy Oncology Group, National Cancer Institute (NCI), American College of Radiology Imaging Network, Eastern Cooperative Oncology Group. RTOG S-0132. A Phase II trial of neoadjuvant/adjuvant STI-571 (Gleevec NSC#716051) for primary and reccurent operable malignant GIST expressing the KIT receptor tyrosine kinase (CD 11). (NCT identifier: NCT00028002) (2009)

247. Eisenberg B.L., Harris J., Blanke C.D., et al.: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Reccurent Operable Gastrointestinal Stromal Tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42-47

248. Mieetinen M., Lasota J.: Gastrointestinal Stromal Tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83

249. De Matteo R.P., Gold J.S., Saran L., et al.: Tumor Mitotic Rate, Size, and Location Indepedently Predict Recurrence After Resection of Primary Gastrointestinal Stromal Tumor (GIST). Cancer 2008; 112: 608-615

250. De Matteo R.P., Owzar K., Antonescu C.R., et al.: Efficacy of Adjuvant Imatinib Mesylate Following Complete Resection of Localized Primary Gastrointestinal Stromal Tumor (GIST) at High Risk of Recurrence. The U.S. Intergroup Phase II Trial ACOSOG Z9000. Gastrointest. Cancers Sympos. Orlando,FL,USA, Jan. 2008, (abstr. 8)

251. De Matteo R.P., Owzar K., Maki R., et al.: Adjuvant Imatinib Mesylate Increases Recurrence Free Survival (RFS) in Patients with Completed Resected Localized Primary Gastrointestinal Tumor (GIST): North American Inergroup Phase III Trial ACOSOG Z9001. ASCO Annual Meeting. Chicago,IL,USA, Jun 2007 (abstr. 10079)

252. De Matteo R.P., Ballman K. V., Antonescu C.R., et al.: Adjuvant Imatinib Mesylate After Resection of Localised , Primary Gastrointestinal Stromal Tumor: a randomised Double-blind, Placebo-controlled Trial. Lancet 2009; 373: 1097-1104

253. Shen L., Li J., Li J., et al.: Adjuvant Post-Surgery Therapy with Imatinib in Intermediate or High-Risk Gastrointestinal Stromal Tumour (GIST) Patients: Interim Analysis from a Single Centre Comparison Study. Ann Oncol 2008; 19(suppl. 8),Viii 267 (abstr. 870 PD)

254. Kang Y., Kang B.W., Ryu M., et al.: A Phase II Study of Imatinib Mesylate as Adjuvant Treatment for Curatively Resected High-Risk Localized Gastrointestinal Stromal Tumors with c-KIT  exon 11 Mutation. Gastrointest. Cancers Sympos. Science and Multidisciplinary Management of GI Malignancies. Jan. 2009, San Frasisco, CA,USA, (abstr. 95)

255. European Organization for Research and Treatment of Cancer, Italian Sarcoma Group, Federation Nationale des Centres de Lutte Centre le Cancer, Sarcomas Gedle. EORTC 62024. Intermediate and High Risk Localized, Completly Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: a controlled randomized trial on adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery. (NTC identifier: NCT00103168) (2009)

256. Scandinavian Sarcoma Group. SSGXVIII/AIO. Short (12 months) Versus Long (36 months) Duration of Adjuvant Treatment with the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST with a High Risk of Recurrence. (NCT identifier: NCT00116935) (2009)

H παρούσα μελέτη ουδεμίας χορηγίας ή επιχορηγήσεως έτυχε. Οι παρεχόμενες εδώ πληροφορίες δεν θα πρέπει να υποκαταστήσουν την παροχή συμβουλών από εξειδικευμένους πάροχους υγείας. Τουναντίον, οι πληροφορίες αυτές έχουν εκπαιδευτικό χαρακτήρα και ενημερωτικό σκοπό αποτεινόμενο προς συναδέλφους ιατρούς. Κατ’ ουδένα τρόπο πρέπει να θεωρούνται ιατρικές συμβουλές παρεχόμενες προς ασθενείς. Παρακαλείσθε όπως αναζητήσετε κατάλληλη ιατρική συμβουλή, εάν έχετε υποψίες ότι πάσχετε από ανάλογες παθήσεις.

Επιστροφή στο ευρετήριο